Xianjun Yu

31.8k total citations · 14 hit papers
544 papers, 21.6k citations indexed

About

Xianjun Yu is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Xianjun Yu has authored 544 papers receiving a total of 21.6k indexed citations (citations by other indexed papers that have themselves been cited), including 357 papers in Oncology, 190 papers in Molecular Biology and 143 papers in Epidemiology. Recurrent topics in Xianjun Yu's work include Pancreatic and Hepatic Oncology Research (262 papers), Neuroendocrine Tumor Research Advances (118 papers) and Lung Cancer Research Studies (56 papers). Xianjun Yu is often cited by papers focused on Pancreatic and Hepatic Oncology Research (262 papers), Neuroendocrine Tumor Research Advances (118 papers) and Lung Cancer Research Studies (56 papers). Xianjun Yu collaborates with scholars based in China, United States and Canada. Xianjun Yu's co-authors include Jin Xu, Si Shi, Chen Liang, Jie Hua, Qingcai Meng, Quanxing Ni, Chen Liu, Guopei Luo, Liang Liu and Jiang Long and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Xianjun Yu

522 papers receiving 21.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives

2021 1.4k citations Jin Xu, Wei Wang et al. profile →
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity

2020 930 citations Jin Xu, Bo Zhang et al. profile →
The role of necroptosis in cancer biology and therapy

2019 782 citations Kaizhou Jin, Quanxing Ni et al. profile →
Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research

2022 575 citations Mingming Xiao, Jin Xu et al. profile →
The role of collagen in cancer: from bench to bedside

2019 542 citations Huaxiang Xu, Wenquan Wang et al. profile →
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype

2017 417 citations Xianjun Yu et al. profile →
Applications of single-cell sequencing in cancer research: progress and perspectives

2021 346 citations Jin Xu, Bo Zhang et al. profile →
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter

2020 251 citations Kaizhou Jin, Cheng He et al. profile →
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets

2023 190 citations Jin Xu, Xianjun Yu et al. profile →
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives

2022 151 citations Qingcai Meng, Jin Xu et al. Cancer Communications profile →
Liquid–liquid phase separation in tumor biology

2022 142 citations Jin Xu, Wei Wang et al. profile →
Functional significance of cholesterol metabolism in cancer: from threat to treatment

2023 111 citations Mingming Xiao, Jin Xu et al. profile →
Lactate‐induced protein lactylation: A bridge between epigenetics and metabolic reprogramming in cancer

2023 107 citations Ye Zeng, Guixiong Fan et al. profile →
Histone lactylation: from tumor lactate metabolism to epigenetic regulation

2024 61 citations Xianjun Yu, Si Shi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xianjun Yu China	70	9.9k	9.1k	6.5k	4.0k	3.9k	544	21.6k
Timothy A. Chan United States	77	9.4k 0.9×	10.4k 1.1×	5.2k 0.8×	4.5k 1.1×	5.5k 1.4×	243	22.7k
Rolf A. Brekken United States	73	9.3k 0.9×	6.4k 0.7×	4.4k 0.7×	3.5k 0.9×	1.7k 0.4×	271	19.5k
Diane M. Simeone United States	68	9.9k 1.0×	11.5k 1.3×	4.8k 0.7×	3.1k 0.8×	1.8k 0.5×	286	20.7k
Eli Pikarsky Israel	54	8.8k 0.9×	5.0k 0.5×	4.8k 0.7×	3.6k 0.9×	2.3k 0.6×	135	18.1k
William E. Grizzle United States	82	14.1k 1.4×	6.3k 0.7×	6.4k 1.0×	3.9k 1.0×	3.3k 0.9×	499	26.2k
Jörg Kleeff Germany	79	8.7k 0.9×	14.3k 1.6×	4.5k 0.7×	2.7k 0.7×	3.7k 0.9×	424	23.3k
Yue Xu China	47	8.9k 0.9×	5.0k 0.5×	4.7k 0.7×	4.3k 1.1×	4.8k 1.2×	211	17.8k
Surinder K. Batra United States	84	14.4k 1.5×	9.3k 1.0×	4.1k 0.6×	4.1k 1.0×	3.1k 0.8×	580	25.5k
Hongyang Wang China	79	12.2k 1.2×	4.6k 0.5×	6.6k 1.0×	3.6k 0.9×	1.6k 0.4×	486	22.0k
Michael Zeisberg Germany	55	10.6k 1.1×	5.6k 0.6×	3.6k 0.6×	2.1k 0.5×	3.3k 0.9×	105	21.1k

Countries citing papers authored by Xianjun Yu

Since Specialization

Citations

This map shows the geographic impact of Xianjun Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xianjun Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xianjun Yu more than expected).

Fields of papers citing papers by Xianjun Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xianjun Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xianjun Yu. The network helps show where Xianjun Yu may publish in the future.

Co-authorship network of co-authors of Xianjun Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Xianjun Yu. A scholar is included among the top collaborators of Xianjun Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xianjun Yu. Xianjun Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zeng, Lelin, et al.. (2025). A novel pairwise diastereomeric crystallization-unconventional electrodialysis method for sustainable chiral resolution of α-phenylethylamine and mother liquor reuse. Journal of Membrane Science. 722. 123873–123873. 1 indexed citations

Wang, Wei, Jie Hua, Jingyao Zhang, et al.. (2025). SMUG1 promoted the progression of pancreatic cancer via AKT signaling pathway through binding with FOXQ1. Chinese Medical Journal. 138(20). 2640–2656.

Xiao, Mingming, Yangyi Li, Jintong Na, et al.. (2025). The Role of Senescence, its Therapeutic Relevance and Clinical Implications in the Tumor Microenvironment. Theranostics. 15(16). 8675–8703.

Tong, Xuhui, Rong Tang, Jin Xu, et al.. (2025). Cancer type-specific adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis. Heliyon. 11(1). e41597–e41597.

Zhuo, Qifeng, Borui Li, Mengqi Liu, et al.. (2024). Feasibility of laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer: a retrospective cohort study. World Journal of Surgical Oncology. 22(1). 1–1. 5 indexed citations

Wang, Xu, Xuan Lin, Xuan Zou, et al.. (2024). Antigen/HLA-agnostic strategies for Characterizing Tumor-responsive T cell receptors in PDAC patients via single-cell sequencing and autologous organoid application. Cancer Letters. 588. 216741–216741. 8 indexed citations

Hu, Rong, et al.. (2024). The association of the perioperative neutrophil-to-lymphocyte ratio with wound healing in patients with Wagner grade 3 and 4 diabetic foot ulcers after tibial cortex transverse transport surgery: a prospective observational cohort study. Frontiers in Endocrinology. 15. 1420232–1420232.

Yu, Xianjun, Xiaofeng Zhang, J. J. Liu, et al.. (2024). 132MO Anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC): Updated results from a phase I study. Annals of Oncology. 35. S1456–S1456. 2 indexed citations

Wei, Miaoyan, Rujiao Liu, Xiaobing Chen, et al.. (2024). Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma. BMC Medicine. 22(1). 365–365.

10.

Wang, Jingyi, Xiaohong Wang, Chenjie Zhou, et al.. (2024). YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer. Cancer Letters. 602. 217197–217197. 3 indexed citations

11.

Hua, Jie, Liang Chen, Bo Zhang, et al.. (2023). Reappraisal of Tumor Deposit as a Prognostic Factor in Pancreatic Cancer. Annals of Surgical Oncology. 30(5). 3038–3044. 1 indexed citations

12.

Li, Zheng, Haidi Chen, Borui Li, et al.. (2023). Holistic anti-tumor resistance mechanism of YBX1 and its potential as a chemoresistance target in pancreatic ductal adenocarcinoma. 2(1). 2 indexed citations

13.

Guerrero, Natalie, Xianjun Yu, Jean L. Raphael, & Teresia M. O’Connor. (2023). 9. Impacts of Racial Discrimination in Late Adolescence on Psychological Distress and Wellbeing Outcomes in the Transition to Adulthood. Journal of Adolescent Health. 72(3). S2–S2. 2 indexed citations

14.

Wang, Ting, Yi Qin, Ye Zeng, et al.. (2023). A new glance at autophagolysosomal-dependent or -independent function of transcriptional factor EB in human cancer. Acta Pharmacologica Sinica. 44(8). 1536–1548. 12 indexed citations

15.

Gao, Heli, Wuhu Zhang, Huaxiang Xu, et al.. (2022). The optimal duration of capecitabine plus temozolomide in patients with well‐differentiated pancreatic NETs with or without maintenance therapy. Journal of Neuroendocrinology. 34(6). e13112–e13112. 1 indexed citations

16.

Meng, Qingcai, Jin Xu, Wei Wang, et al.. (2022). Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives. Cancer Communications. 43(1). 3–41. 151 indexed citations breakdown →

17.

Liang, Chen, Si Shi, Yi Qin, et al.. (2019). Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer. Gut. 69(5). 888–900. 120 indexed citations

18.

Liang, Chen, Yi Qin, Bo Zhang, et al.. (2017). Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Research. 15(2). 201–212. 46 indexed citations

19.

Ji, Shunrong, Yi Qin, Chen Liang, et al.. (2016). FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer. Clinical Cancer Research. 22(15). 3950–3960. 76 indexed citations

20.

Zhang, Fei, Bin Liu, Zhen Wang, et al.. (2013). A Novel Regulatory Mechanism of Pim-3 Kinase Stability and Its Involvement in Pancreatic Cancer Progression. Molecular Cancer Research. 11(12). 1508–1520. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact